Mark Groot's Contact Details

Mark Groot's Company Details

Pattern Pharma

Toronto, ON, CA • 5 - 9 Employees
Major Drugs

Pattern is an immunotherapy company whose lead product candidate, P2PAR-100, is a TLR agonist that activates the innate immune system safely and effectively. P2PAR-100 works by activating key innate immune cells including macrophages, dendritic cells (DCs) and natural killer cells. In addition, P2PAR-100 also mobilizes the adaptive immune system (via DCs) and creates protective immune memory through a process of in situ vaccination. Pattern's initial focus is on HPV-related cancers. Despite the availability of preventive HPV vaccines, HPV prevalence remains high and HPV-associated cancers remain a significant health concern worldwide. It is estimated that 5% of all cancers worldwide are attributable to HPV, with more than 600,000 new cancer cases per year. Other pipeline opportunities include cancers caused by viruses (10% of cancers), cancers caused by infections (15% of cancers), as well as combination therapy opportunities with conventional cancer therapies, other immuno-therapies such as checkpoint inhibitors, and aging-related immunosenescence.Pattern has ongoing preclinical and clinical development collaborations with MD Anderson Cancer Center (MDACC), Massachusetts General Hospital, McGill University, and other institutions, and aims to commence its Phase 1a/b clinical study in solid tumors & HPV-associated cancers at MDACC in early 2023.